



ASX ANNOUNCEMENT

Investor Briefing on new Hologic Agreements

MELBOURNE, Australia (15 January 2024) – Lumos Diagnostics Holdings Ltd (ASX:LDX, “Lumos” or the “Company”) a leader in rapid, point-of-care (POC) diagnostic technologies, is pleased to invite investors to attend an online briefing on its two new agreements with leading global women’s health company, Hologic, Inc. (NASDAQ:HOLX) (ASX announcement: 11 January 2024).

Investor briefing webinar:

Existing and potential investors are invited to attend a webinar hosted by Lumos CEO, Doug Ward and CFO, Barrie Lambert, covering additional background on the two new (Development and IP) agreements with US based women's health company Hologic, Inc.

The webinar will be held on Tuesday 16 January 2024 at 10:30am AEDT.

Participants can register ahead of time using the following link:

https://us02web.zoom.us/webinar/register/WN_byIXAPZIRHexEYUMxn7O5Q

Once the registration form is completed, investors will receive a confirmation link with details on how to access the briefing.

A Q&A session will follow the management presentation. Investors are invited to submit questions prior to the webinar to Jane Lowe via jane.lowe@irdepartment.com.au.

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader

platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contact:

Haley Chartres – Australia
H[^]CK Director
haley@hck.digital
+61 (0) 423 139 163

Investor Contact:

Jane Lowe
Managing Director, IR Department
ir@lumosdiagnostics.com
+61 411 117 774

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205, Australia
+61 3 9087 1598